In addition, DOT1L inhibitor-induced losses of H3K79me at enhancers in leukemia cells has been correlated with reduced levels of H3K27 acetylation and reduced chromatin accessibility (probed by ATAC-seq) [86,87]. This evidence concerns the gene DOT1L and leukemia.